Bozinoff Nikki, Lei Jingxin, Mihic Tamara, Moe Jessica, Palis Heather, Nolan Seonaid, Ti Lianping, Kennedy Mary Clare
J Addict Med. 2025 Mar 27. doi: 10.1097/ADM.0000000000001483.
To characterize patterns of outpatient buprenorphine induction and examine factors associated with the use of low-dose initiation (LDI).
A retrospective cohort study of 4510 adults initiating buprenorphine between January 1, 2016 and December 31, 2019 in British Columbia (BC), Canada, was undertaken using linked administrative data in the Provincial Overdose Cohort, which contains a 20% random sample of BC residents. Using multivariable modelling, we examined the association between sociodemographic, co-morbidity, treatment, and health service utilization variables, and the outcome of LDI. Joinpoint analysis was also conducted to assess inflection points in the prevalence of this practice.
Overall, 7.2% of included buprenorphine inductions during the study period were classified as LDI. Joinpoint analysis revealed that the percentage of buprenorphine inductions classified as LDI increased significantly beginning in the fourth quarter of 2017. In multivariable analyses, factors positively associated with LDI included: older age (adjusted odds ratio [aOR]: 1.01, 95% CI: 1.00-1.02), living in Vancouver Coastal (aOR: 1.53, 95% CI: 1.13-2.06) and Fraser Health Authority regions (aOR: 2.56, 95% CI: 1.89-3.48) (vs interior region); having been prescribed slow-release oral morphine for opioid use disorder in the last 3 years (aOR: 4.03, 95% CI: 2.51-6.49), and having 1 (aOR: 2.40, 95% CI: 1.80-3.20) or ≥2 (vs 0) opioid agonist treatment episodes in the last 5 years (aOR: 2.56, 95% CI: 1.89-3.48). Factors negatively associated with microinduction included: male sex (aOR: 0.50, 95% CI:0.41-0.61), alcohol use disorder (aOR: 0.62, 95% CI: 0.40-0.96), injection drug use (aOR: 0.75, 95% CI: 0.61-0.94) and past-year incarceration (aOR: 0.19, 95% CI: 0.10-0.33).
The use of LDI has increased in BC in recent years. Markers of treatment experience were positively associated with receipt of LDI. A ssessment of outcomes associated with LDI is needed.
描述门诊丁丙诺啡诱导模式,并研究与低剂量起始使用(LDI)相关的因素。
采用加拿大不列颠哥伦比亚省(BC)省级过量用药队列中的关联行政数据,对2016年1月1日至2019年12月31日期间在BC省开始使用丁丙诺啡的4510名成年人进行回顾性队列研究,该队列包含BC省居民20%的随机样本。通过多变量建模,我们研究了社会人口统计学、合并症、治疗和卫生服务利用变量与LDI结果之间的关联。还进行了连接点分析,以评估这种做法流行率的拐点。
总体而言,研究期间纳入的丁丙诺啡诱导治疗中,7.2%被归类为LDI。连接点分析显示,自2017年第四季度开始,被归类为LDI的丁丙诺啡诱导治疗百分比显著增加。在多变量分析中,与LDI呈正相关的因素包括:年龄较大(调整优势比[aOR]:1.01,95%置信区间[CI]:1.00 - 1.02)、居住在温哥华沿海地区(aOR:1.53,95%CI:1.13 - 2.06)和弗雷泽卫生局辖区(aOR:2.56,95%CI:1.89 - 3.48)(相对于内陆地区);在过去3年中因阿片类药物使用障碍被开具缓释口服吗啡(aOR:4.03,95%CI:2.51 - 6.49),以及在过去5年中有1次(aOR:2.40,95%CI:1.80 - 3.20)或≥2次(相对于0次)阿片类激动剂治疗发作(aOR:2.56,95%CI:1.89 - 3.48)。与小剂量诱导呈负相关的因素包括:男性(aOR:0.50,95%CI:0.41 - 0.61)、酒精使用障碍(aOR:0.62,95%CI:0.40 - 0.96)、注射吸毒(aOR:0.75,95%CI:0.61 - 0.94)和过去一年曾被监禁(aOR:0.19,95%CI:0.10 - 0.33)。
近年来,BC省LDI的使用有所增加。治疗经验指标与接受LDI呈正相关。需要评估与LDI相关的结果。